145 related articles for article (PubMed ID: 38685118)
1. Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation.
Alexis A; Del Rosso JQ; Forman S; Martorell A; Browning J; Laquer V; Desai SR; York JP; Chavda R; Dhawan S; Moore AY; Stein-Gold L
Int J Dermatol; 2024 Jun; 63(6):806-815. PubMed ID: 38685118
[TBL] [Abstract][Full Text] [Related]
2. A review of the topical management of acne and its associated sequelae in the Asia-Pacific region with a spotlight on trifarotene.
See JA; Chavda R; Kon KM; Goodman GJ; Oblepias MS; Nadela RE; Oon HH; Aurangabadkar S; Suh DH; Chan HHL; Lahiri K
Int J Dermatol; 2024 Jun; 63(6):704-713. PubMed ID: 38643368
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
Tan J; Thiboutot D; Popp G; Gooderham M; Lynde C; Del Rosso J; Weiss J; Blume-Peytavi U; Weglovska J; Johnson S; Parish L; Witkowska D; Sanchez Colon N; Alió Saenz A; Ahmad F; Graeber M; Stein Gold L
J Am Acad Dermatol; 2019 Jun; 80(6):1691-1699. PubMed ID: 30802558
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.
Blume-Peytavi U; Fowler J; Kemény L; Draelos Z; Cook-Bolden F; Dirschka T; Eichenfield L; Graeber M; Ahmad F; Alió Saenz A; Rich P; Tanghetti E
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):166-173. PubMed ID: 31306527
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Jessner's solution peel in comparison with salicylic acid 30% peel in the management of patients with acne vulgaris and postacne hyperpigmentation with skin of color: a randomized, double-blinded, split-face, controlled trial.
How KN; Lim PY; Wan Ahmad Kammal WSL; Shamsudin N
Int J Dermatol; 2020 Jul; 59(7):804-812. PubMed ID: 32447767
[TBL] [Abstract][Full Text] [Related]
6. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
Han G; Armstrong AW; Desai SR; Guenin E
J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes in Acne Patients With Skin of Color Using Adapalene 0.3%-Benzoyl Peroxide 2.5%: A Prospective Real-World Study.
DuBois J; Ong GCW; Petkar G; Almeida LMC; Chavda R; Kerrouche N; Alexis AF
J Drugs Dermatol; 2019 Jun; 18(5):514. PubMed ID: 31251543
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
Mazzetti A; Moro L; Gerloni M; Cartwright M
J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
[TBL] [Abstract][Full Text] [Related]
9. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
10. Trichloroacetic acid model to accurately capture the efficacy of treatments for postinflammatory hyperpigmentation.
Lyons AB; Kohli I; Nahhas AF; Braunberger TL; Mohammad TF; Nicholson CL; Nartker NT; Modi K; Matsui MS; Lim HW; Hamzavi IH
Arch Dermatol Res; 2020 Dec; 312(10):725-730. PubMed ID: 32253506
[TBL] [Abstract][Full Text] [Related]
11. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
12. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
Lain E; Day D; Harper J; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
[TBL] [Abstract][Full Text] [Related]
13. Trifarotene for the Treatment of Facial and Truncal Acne.
Bell KA; Brumfiel CM; Haidari W; Boger L
Ann Pharmacother; 2021 Jan; 55(1):111-116. PubMed ID: 32567361
[TBL] [Abstract][Full Text] [Related]
14. Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD; Baldwin H; Cook-Bolden FE; Alexis AF; Stein Gold L; Guenin E
Am J Clin Dermatol; 2022 Jan; 23(1):69-81. PubMed ID: 34751927
[TBL] [Abstract][Full Text] [Related]
15. Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series.
Del Rosso JQ; Lain E; York JP; Alexis A
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2189-2200. PubMed ID: 35994159
[TBL] [Abstract][Full Text] [Related]
16. Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.
Schleicher S; Moore A; Rafal E; Gagne-Henley A; Johnson SM; Dhawan S; Chavda R; York JP; Sforzolini B; Holcomb K; Ablon G; Del Rosso J; Dreno B
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3085-3096. PubMed ID: 37838987
[TBL] [Abstract][Full Text] [Related]
17. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
Grimes P; Callender V
Cutis; 2006 Jan; 77(1):45-50. PubMed ID: 16475496
[TBL] [Abstract][Full Text] [Related]
18. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
Taylor SC; Cook-Bolden FE; McMichael A; Downie JB; Rodriguez DA; Alexis AF; Callender VD; Alvandi N
J Drugs Dermatol; 2018 Feb; 17(2):160-167. PubMed ID: 29462223
[TBL] [Abstract][Full Text] [Related]
20. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
Stein Gold L; Pariser DM; Guenin E
J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
